FindTrial
Sign In

A Double Blind, Randomised, Placebo Controlled Study of Farlutal in the Treatment of Weight Loss in Patients Undergoing Radiotherapy for Head and Neck Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN72126158
Enrollment
Unknown
Registered
2002-08-19
Start date
2000-08-19
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancer Cancer Head and Neck Cancer

Interventions

1. Group A: Oral medroxyprogesterone acetate 500 mg twice daily for a maximum of 12 weeks 2. Group B: Placebo tablets twice daily for a maximum of 12 weeks

Sponsors

Farmitalia Carlo Erba (Italy)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Aged >18 years 2. Squamous cell carcinoma of the head and neck 3. Not known to have or suspected of having early breast cancer 4. No known hypersensitivity to medroxyprogesterone acetate 5. No medical contraindications to treatment

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Secondary

MeasureTime frame
Not provided at time of registration—

Primary

MeasureTime frame
Not provided at time of registration—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026